138 related articles for article (PubMed ID: 38238163)
1. Rare
Chau L; Nael A; Sato M; Crawford JR
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38238163
[No Abstract] [Full Text] [Related]
2. Pleomorphic xanthoastrocytoma in the brainstem with BRAF V600E mutation: A case report.
Guo Y; Ning G; Feng M; Qu HB
Asian J Surg; 2023 Aug; 46(8):3371-3373. PubMed ID: 36977615
[No Abstract] [Full Text] [Related]
3. BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma.
Pratt D; Camelo-Piragua S; McFadden K; Leung D; Mody R; Chinnaiyan A; Koschmann C; Venneti S
Acta Neuropathol Commun; 2018 Mar; 6(1):24. PubMed ID: 29544532
[No Abstract] [Full Text] [Related]
4. Rare case of
Yang JH; Tucker SM; Levy ML; Crawford JR
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637515
[No Abstract] [Full Text] [Related]
5. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
Brown NF; Carter T; Mulholland P
CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
[TBL] [Abstract][Full Text] [Related]
7. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
Lukas RV; Merrell RT
CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
[TBL] [Abstract][Full Text] [Related]
8. Identification of
Huang W; Cai J; Lin N; Xu Y; Wang H; Wu Z; Kang D
AJNR Am J Neuroradiol; 2021 Dec; 42(12):2152-2159. PubMed ID: 34725042
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
Sugiura Y; Nagaishi M
J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
[TBL] [Abstract][Full Text] [Related]
10. [Anaplastic pleomorphic xanthoastrocytoma - single-center analysis of 42 patients].
Belyaev AY; Shugai SV; Kobyakov GL; Strunina YV; Batalov AI; Pronin IN; Usachev DY
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(2):45-54. PubMed ID: 35412712
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
Kim SH; Hwang K; Lee KS; Choe G; Kim CY
World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
Purkait S; Bansal S; Malgulwar PB
Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
[TBL] [Abstract][Full Text] [Related]
13. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
[TBL] [Abstract][Full Text] [Related]
14. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA).
Hofer S; Berthod G; Riklin C; Rushing E; Feilchenfeldt J
Acta Oncol; 2016; 55(1):122-3. PubMed ID: 25811650
[No Abstract] [Full Text] [Related]
16. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation.
Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Jin LW; Bastian BC; Bollen AW; Perry A; Nicolaides T; Solomon DA; Shieh JT
Acta Neuropathol; 2016 Nov; 132(5):757-760. PubMed ID: 27624885
[No Abstract] [Full Text] [Related]
17. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
[TBL] [Abstract][Full Text] [Related]
18. Challenges of targeting
Smith-Cohn M; Davidson C; Colman H; Cohen AL
CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
[No Abstract] [Full Text] [Related]
19. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
[TBL] [Abstract][Full Text] [Related]
20. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
